Editorial: Targeting major human fungal pathogens: novel insights into virulence and antifungal therapies

The global burden of invasive fungal infections continues to escalate, driven by an expanding population of immunocompromised patients, climate-mediated emergence of new pathogens, and the relentless acquisition of multidrug resistance [1][2][3] Taken together, the Topic reframes fungal pathogenesis as a systems-level problem in which metabolic wiring, environmental resistance reservoirs, host immunity, and biofilm architecture converge. The original articles furnish mechanistic entry points-natural-product scaffolds, nutrient transporters, RNA-binding proteins, and efflux regulators-while the reviews contextualize these discoveries within therapeutic, technological, and ecological landscapes. We hope this integrative snapshot equips researchers, clinicians, and policy makers with the conceptual and practical tools required to accelerate the next wave of antifungal innovations and, ultimately, to reduce the unacceptably high morbidity and mortality inflicted by these formidable pathogens.